Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Kidney Cancer Diagnostics And Therapeutics Market Expected To Become By 2029 Compared With Its 2025 Level?
The kidney cancer diagnostics and therapeutics market size has experienced robust expansion over the past few years. It is anticipated to increase from $4.1 billion in 2024 to $4.31 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.1%. Historically, the market’s growth has been driven by factors including research on molecular biology, clinical trials and drug development, surgical innovations, genetic discoveries, and improvements in healthcare access.
The kidney cancer diagnostics and therapeutics market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $5.65 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this anticipated growth during the forecast period include progress in biomarker research, developments in genomic sequencing, the rise of telemedicine and remote consultations, breakthroughs in precision medicine, and the emergence of rapid diagnostic technologies. Significant trends expected within the forecast timeframe encompass the integration of palliative care, enhanced long-term survivorship care, increased focus on nutrition and lifestyle intervention, the broader application of radiomics, and the wider adoption of liquid biopsies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp
Which Drivers Are Shaping The Kidney Cancer Diagnostics And Therapeutics Industry’s Market Share?
The escalating incidence of kidney cancer is projected to stimulate expansion within the kidney cancer diagnostics and therapeutics market. This condition occurs when typical cells in one or both kidneys undergo abnormal alterations and exhibit unrestrained proliferation, forming a mass known as a renal cortical tumor. Diagnostics and therapeutics for kidney cancer are essential for disease management and patient care, offering benefits such as prompt identification, accurate diagnosis, selection of appropriate treatments, personalized medical approaches, and ongoing treatment monitoring. For instance, in March 2023, data from the American Society of Clinical Oncology (ASCO), a US-based non-profit organization dedicated to cancer care, indicated that 81,800 individuals in the United States are anticipated to be diagnosed with kidney cancer in 2023 (comprising 52,360 males and 29,440 women). Moreover, globally, kidney cancer had affected 431,288 individuals in 2020. Therefore, the rising prevalence of kidney cancer is expected to fuel the growth of the kidney cancer diagnostics and therapeutics market.
Which Key Segments Fueling The Kidney Cancer Diagnostics And Therapeutics Market?
The kidney cancer diagnostics and therapeuticsmarket covered in this report is segmented –
1) By Cancer Type: Clear Cell RCC; Papillary RCC; Chromophobe RCC; Urothelial Carcinoma And Transitional Cell Carcinoma; Other Cancer Types
2) By Component: Drugs; Diagnostics
3) By Diagnostics: Biopsy; CT Scan; Nephro-Ureteroscopy; Intravenous Pyelogram; Ultrasound
4) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy
5) By End-Users: Hospitals; Pharmaceutical Labs; Genomics Laboratories
Subsegments:
1) By Clear Cell RCC: Stage I; Stage II; Stage III; Stage IV
2) By Papillary RCC: Type 1; Type 2
3) By Chromophobe RCC: Localized; Advanced
4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-muscle invasive; Muscle invasive; Metastatic
5) By Other Cancer Types: Collecting Duct Carcinoma; Renal Medullary Carcinoma; Other rare types
Which Market Trends Are Creating New Opportunities In The Kidney Cancer Diagnostics And Therapeutics Industry?
Major companies in the kidney cancer diagnostics and therapeutics market are prioritizing the advancement of renal cell carcinoma (RCC) treatments to enhance patient outcomes and deliver innovative, customized therapeutic options for individuals diagnosed with this challenging condition. Research into renal cell carcinoma (RCC) is vital for kidney cancer diagnostics and therapeutics, as it stimulates the development of novel diagnostic approaches and targeted treatments that improve early detection and personalized patient care. For instance, in December 2023, Merck, a US-based pharmaceutical firm, introduced welireg (belzutifan), the inaugural hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor sanctioned for adult patients with advanced renal cell carcinoma (RCC) following previous treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This new therapeutic class demonstrates substantial benefits, including better progression-free survival and increased response rates compared to everolimus. The approval of WELIREG marks a significant breakthrough in the kidney cancer diagnostics and therapeutics market, presenting new possibilities for patients with progressing disease.
Which Leading Companies Dominate The Kidney Cancer Diagnostics And Therapeutics Market Share?
Major companies operating in the kidney cancer diagnostics and therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited
Download The Full Report For Exclusive Market Findings:
How Is Kidney Cancer Diagnostics And Therapeutics Market Demand Varying Across Different Regions?
North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Kidney Cancer Diagnostics And Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=11937&type=smp
Browse Through More Reports Similar to the Global Kidney Cancer Diagnostics And Therapeutics Market 2025, By The Business Research Company
Pain Management Devices And Therapies Global Market Report 2025
Metabolomics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report
Isothermal Nucleic Acid Amplification Technology Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model